Gilead Sciences licenses three preclinical antiviral programs from Novartis appeared first on PharmaNewsDaily.com.

" /> Gilead Sciences licenses three preclinical antiviral programs from Novartis - Business News Today
Published On: Mon, Jul 22nd, 2019

Gilead Sciences licenses three preclinical antiviral programs from Novartis

US biopharma company Gilead Sciences has licensed three preclinical antiviral programs, including investigational candidates having the potential to treat human rhinovirus, influenza and herpes viruses, from Swiss pharma company Novartis.

As per the agreement, Gilead Sciences will get exclusive global rights for the development and commercialization of small molecules against three undisclosed targets. Novartis will get an undisclosed upfront payment apart from an additional $291 million in the form of potential milestone payments based on certain development and commercial milestones, and also as royalties on yearly net sales.

John McHutchison – Gilead Sciences Chief Scientific Officer and Head of Research and Development, said: “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options.

The antiviral portfolio of Gilead Sciences includes for the of HIV, hepatitis B, and hepatitis C, and also influenza infection.

Gilead Sciences licenses three preclinical antiviral programs from Novartis
Gilead Sciences licenses three preclinical antiviral programs from Novartis. Photo courtesy of Stuart Miles/Freedigitalphotos.net.

Related posts

The post Gilead Sciences licenses three preclinical antiviral programs from Novartis appeared first on PharmaNewsDaily.com.

No tags for this post.

Recent Posts